The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post ‐Hoc Analyses on the First 3 Weeks of Treatment

ConclusionFremanezumab treatment resulted in a rapid preventive response in patients with HFEM, with reductions seen in several headache parameters and migraine symptoms within the first week after therapy initiation and continuing during the second and third weeks. Patients also were able to rapidly reduce their use of acute medications to treat migraine attacks. The trial is registered at Clinicaltrials.gov as NCT02025556.

Source: Headache: The Journal of Head and Face Pain - November 18, 2018 Category: Neurology Authors: Stephen D. Silberstein, Alan M. Rapoport, Pippa S. Loupe, Ernesto Aycardi, Mirna McDonald, Ronghua Yang, Marcelo E. Bigal Tags: Research Submission Source Type: research